Related Experiment Video
Updated: Apr 18, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Effects of Daikenchuto (TJ-100) After Gastrointestinal Oncological Surgery: An Updated Meta-Analysis of Randomized
Gabriele Eckerdt Lech1, Luiza Bertolli Lucchese Moraes1, Carolina Moronte Sturmer1
1Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.
Introduction:
Daikenchuto is an herbal medicine that has been shown to improve gastrointestinal motility. Therefore, we aimed to perform a meta-analysis to evaluate the use of daikenchuto in patients undergoing gastrointestinal oncological surgery.
Methods:
We searched PubMed, Embase, and Cochrane Central for randomized controlled trials (RCTs) comparing daikenchuto with control (placebo or no medicine) in patients undergoing gastrointestinal oncological surgery. Statistical analysis was performed using R statistical software 4.2.1. Heterogeneity was assessed with I2.
Results:
We included 1,158 patients from 9 RCTs. Daikenchuto significantly reduced the time to first bowel movement (TFBM) (mean difference [MD] -11.15 hours; 95% CI: -16.96--5.34; P < .001), and the length of hospital stay (MD -0.5 days; 95% CI: -0.92--0.07; P = .022). The time to initial flatus (TIF) (MD -8.82; 95% CI: -18.34 to 0.69; P = .069) and the postoperative ileus incidence (OR: 0.98; 95% CI: 0.58 to 1.64; P = .934) presented no differences between groups. Subgroup analyses yielded no differences between open and laparoscopic approaches in TFBM (P = .91). In TIF, the results presented differences between groups (P < .01) and a significant reduction for the laparoscopic approach (MD -14.54 hours; 95% CI: -22.04--7.05; P < .01). When considering the type of cancer (foregut vs colorectal), we found no differences between groups in TFBM (P = .57), despite a reduction in colorectal surgery alone (MD -12.64 hours; 95% CI: -20.22--5.06; P = .001). For TIF, colorectal surgery was also associated with a reduction (MD -14.54 hours; 95% CI: -22.04--7.05; P < .01). Trial sequential analysis supported a beneficial effect for daikenchuto in the TFBM outcome.
Conclusion:
Our findings demonstrated a decrease in intestinal motility time and length of hospital stay with the use of daikenchuto, providing valuable evidence for the clinical context, particularly in consideration of laparoscopic and colorectal surgeries.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Appendicitis-II: Diagnostic Studies and Management
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease

